Fingolimod in COVID-19

Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04280588

Enrollment

Registered

2020-02-21

Start date

2020-02-22

Completion date

2020-07-01

Last updated

2020-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Disease (COVID-19)

Brief summary

Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2 pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane formation, timely and appropriate use of immune modulator together with ventilator support should be considered for the severe patients to prevent ARDS development. The sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology modulator which has been widely used in multiple sclerosis.The aim of this study was to determine whether the efficacy of fingolimod for a novel coronavirus disease (COVID-19).

Interventions

DRUGFingolimod 0.5 mg

Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* The patients who were diagnosed with the common type of NCP (including severe risk factors) and severe cases of new coronavirus pneumonia; * Aged 18 to 85 years; * Patients or authorized family members volunteered to participate in this study and signed informed consent.

Exclusion criteria

* Patients with any history of bradyarrhythmia or atrioventricular blocks * Patients who are participating in other drug clinical trials; * Pregnant or lactating women; * ALT / AST\> 5 ULN, neutrophils \<0.5, platelets less than 50; * Definite diagnosis of rheumatic immune-related diseases; * Long-term oral anti-rejection or immunomodulatory drugs; * Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.

Design outcomes

Primary

Measure	Time frame	Description
The change of pneumonia severity on X-ray images	5 day after fingolimod treatment	The lesion change on X-ray images from day 5 to baseline

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026